Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention?

Circulation. 2004 Apr 27;109(16):e195-6; author reply e195-6. doi: 10.1161/01.CIR.0000127111.19811.F9.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Angioplasty, Balloon, Coronary*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Chemotherapy, Adjuvant
  • Complement C5 / antagonists & inhibitors
  • Complement C5 / immunology
  • Humans
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / pathology
  • Myocardial Infarction / therapy
  • Single-Chain Antibodies
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Complement C5
  • Single-Chain Antibodies
  • pexelizumab